排序方式: 共有16条查询结果,搜索用时 16 毫秒
1.
Matineh Barati Bagherabad Fahimeh Afzaljavan Soodabeh ShahidSales Seyed Mahdi Hassanian Amir Avan 《Journal of cellular biochemistry》2019,120(3):2726-2741
Pancreatic ductal adenocarcinoma (PDAC) is an incidence rate nearly equal to its mortality rate. The poor prognosis of the disease can be explained by the absence of effective biomarkers for screening and early detection, together with the aggressive behavior and resistance to the currently available chemotherapy. The therapeutic failure can also be attributed to the inter-/intratumor genetic heterogeneity and the abundance of tumor stroma that occupies the majority of the tumor mass. Gemcitabine is used in the treatment of PDAC; however, the response rate is less than 12%. A recent phase III trial revealed that the combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin could be an option for the treatment of metastatic PDAC patients with good performance status, although these approaches can result in high toxicity level. Further investigations are required to develop innovative anticancer agents that either improve gemcitabine activity, within novel combinatorial approaches or acts with a better efficacy than gemcitabine. The aim of the current review is to give an overview of preclinical and clinical studies targeting key dysregulated signaling pathways in PDAC. 相似文献
2.
ShahidSales Soodabeh Mehramiz Mehrane Radmanesh Davood Rastgar-Moghadam Azam Hassanian Seyed Mahdi Khazaei Majid Ghazizade Hamideh Ferns Gordon A. Avan Amir 《Molecular biology reports》2020,47(8):6009-6014
Molecular Biology Reports - Breast cancer is among the most common malignancies in women. Recent studies have shown that polymorphisms in genes involved in the metabolism and transport of... 相似文献
3.
The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy 下载免费PDF全文
4.
Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress 下载免费PDF全文
5.
6.
The prognostic value of MGMT promoter methylation in glioblastoma: A meta‐analysis of clinical trials 下载免费PDF全文
Maryam Moradi Binabaj Afsane Bahrami Soodabeh ShahidSales Marjan Joodi Mona Joudi Mashhad Seyed Mahdi Hassanian Kazem Anvari Amir Avan 《Journal of cellular physiology》2018,233(1):378-386
The DNA repair protein O6‐Methylguanine‐DNA methyltransferase (MGMT) is suggested to be associated with resistance to alkylating agents such as Temozolomide which is being used in treatment of patients with glioblastoma (GBM). Therefore, we evaluated the associations between MGMT promoter methylation and prognosis of patients with glioblastoma (GBM). Data were extracted from publications in Embase, PubMed, and the Cochrane Library. Data on overall survival (OS), progression‐free survival (PFS), and MGMT methylation status were obtained and 4,097 subjects were enrolled. Data from 34 studies showed that MGMT methylated patients had better OS, compared to GBM unmethylated patients (pooled HRs, 0.494; 95%CI 0.412–0.591; p = 0.001). Meta‐analysis of 10 eligible studies reporting on PFS, demonstrated that MGMT promoter methylation was not significantly associated with better PFS (pooled HRs, 0.653; 95%CI 0.414–1.030; p = 0.067). GBM patients with MGMT methylation were associated with longer overall survival, although this effect was not detected for PFS. Moreover, we performed further analysis in patients underwent a comprehensive imaging evaluation. This data showed a significant association with better OS and PFS, although further studies are warranted to assess the value of emerging marker in prospective setting in patients with glioblastoma as a risk stratification biomarker in clinical management of the patients. 相似文献
7.
Genetic variation in the DNA repair pathway as a potential determinant of response to platinum‐based chemotherapy in breast cancer 下载免费PDF全文
8.
9.
Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer 下载免费PDF全文